Rafferty Asset Management, LLC Chinook Therapeutics, Inc. Transaction History

Rafferty Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$18.66 - $38.58 $506,301 - $1.05 Million	27,133 Added 14.98%	208,207 $8 Million
Q1 2023 May 11, 2023	BUY	$21.53 - $26.8 $152,066 - $189,288	7,063 Added 4.06%	181,074 $4.19 Million
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $575,536 - $844,923	30,893 Added 21.59%	174,011 $4.56 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $1.82 Million - $2.43 Million	103,816 Added 264.15%	143,118 $2.81 Million
Q2 2022 Aug 12, 2022	SELL	$12.59 - $18.8 $504,065 - $752,695	-40,037 Reduced 50.46%	39,302 $687,000
Q1 2022 May 13, 2022	BUY	$12.02 - $16.69 $167,979 - $233,242	13,975 Added 21.38%	79,339 $1.3 Million
Q4 2021 Feb 10, 2022	BUY	$10.69 - $16.83 $205,344 - $323,287	19,209 Added 41.62%	65,364 $1.07 Million
Q3 2021 Nov 10, 2021	BUY	$11.5 - $14.86 $237,958 - $307,483	20,692 Added 81.26%	46,155 $589,000
Q2 2021 Aug 10, 2021	BUY	$13.6 - $18.98 $346,296 - $483,287	25,463 New	25,463 $360,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.